ClinicalTrials.gg
WithdrawnNCT07323576INAVO-CRCUpdated Feb 9, 2026

A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer

A Phase 2 interventional study of Inavolisib and Bevacizumab in Colorectal Cancer, sponsored by Hoffmann-La Roche. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Sponsor's decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies in Colorectal Neoplasms by Hoffmann-La Roche — 3 open to participants now, 7 under way, none of them phase 3. Colorectal Neoplasms · Hoffmann-La Roche.

Enrollment
75th of 77
0 · median 96
Started
2026
with 2 others
Phase 2
32 of 111
none open now
Registered
109th of 111
by date

Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 75th largest by enrollment of the 77 interventional ones that give a count, is one of 3 that started in 2026, is one of 32 in phase 2, and was the 109th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This is a blinded Phase 2 study designed to evaluate the safety and efficacy of inavolisib with bevacizumab and chemotherapy, in participants with metastatic colorectal cancer (mCRC) whose tumors have a PIK3CA mutation. The study has a safety run-in period followed by a randomized period.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • PIK3CA-mutated Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) \<=1
  • confirmed adenocarcinoma originating in the colon or rectum of the Stage 4 ( treatment plan does not include resection or curative ablation) per American Joint Committee on Cancer (AJCC) v8
  • per v1.1
  • No prior systemic therapy in the setting
  • Confirmation of biomarker eligibility: documentation of a PIK3CA mutation from either central testing of tissue, or from a validated historically obtained (pre-existing) test of tumor tissue or blood may be used to confirm eligibility
  • Adequate hematologic and organ function within 14 days prior to initiation of study treatment
  • Agreement to adhere to the requirements

Exclusion criteria

Exclusion Criteria:

  • Biomarker eligibility as per definition
  • Type 2 diabetes requiring ongoing systemic treatment at the time of study entry or any history of Type 1 diabetes
  • Residual Grade 2 or higher neuropathy due to prior oxaliplatin exposure (unless the participant is planned to be treated with FOLFIRI)
  • Symptomatic, untreated, or actively progressing
  • History of gastrointestinal (GI) fistula, GI perforation, or intra-abdominal abscess within 6 months prior to Day 1 of Cycle 1
  • Treatment with strong cytochrome P450 (CYP) 3A4 inducers or strong inhibitors within 1 week or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study treatment (only for patients who will receive FOLFIRI)
  • Known positive status with exceptions for well controlled and on stable treatment
  • History of within 5 years prior to screening, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of or death
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Randomized Period: FOLFOX or FOLFIRI + Bevacizumab + Inavolisib

    Participants will receive either FOLFOX or FOLFIRI and Bevacizumab along with Inavolisib.

    Drug: Inavolisib · Drug: Bevacizumab · Drug: FOLFOX · Drug: FOLFIRI

  • Placebo comparator
    Randomized Period: FOLFOX or FOLFIRI + Bevacizumab + Placebo

    Participants will receive either FOLFOX or FOLFIRI and Bevacizumab along with Placebo.

    Drug: Bevacizumab · Drug: FOLFOX · Drug: FOLFIRI · Drug: Placebo

  • Experimental
    Safety Run-in Period: FOLFOX or FOLFIRI + Bevacizumab + Inavolisib

    Participants will receive either FOLFIRI or FOLFOX and Bevacizumab along with Inavolisib.

    Drug: Inavolisib · Drug: Bevacizumab · Drug: FOLFOX · Drug: FOLFIRI

Interventions

  • Participants will receive Inavolisib as per the schedule mentioned in the protocol.

    Also known as: Itovebi, GDC-0077

  • Participants will receive Bevacizumab as per the schedule mentioned in the protocol.

    Also known as: Avastin

  • DrugFOLFOX

    Participants will receive FOLFOX as per the schedule mentioned in the protocol.

  • DrugFOLFIRI

    Participants will receive FOLFIRI as per the schedule mentioned in the protocol.

  • DrugPlacebo

    Participants will receive Placebo as per the schedule mentioned in the protocol.

06

What researchers measure

Primary outcomes

  1. Safety Run-in Period: Percentage of Participants With Adverse Events (AEs)

    Time frame: Approximately 4 Years

  2. Percentage of Participants With an Objective Response Rate

    The percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1.)

    Time frame: From Baseline Untill Radiographic Disease Progression (Approximately 4 Years)

Secondary outcomes

  1. Progression-free Survival (PFS)

    Time from randomization to death from any cause or the first occurrence of disease progression as determined by the investigator according to RECIST v1.1 (whichever occurs first)

    Time frame: From Baseline Untill Radiographic Disease Progression (up to Approximately 4 Years)

  2. Randomized Phase: Overall Survival (OS)

    Defined as the time from randomization to death from any cause

    Time frame: From Baseline Untill Death (up to Approximately 4 Years)

  3. Randomized Phase: Disease Control Rate (DCR)

    Defined as the percentage of participants with stable disease for \>=12 weeks or a CR or PR as determined by the investigator according to RECIST v1.1

    Time frame: From Baseline Untill Disease Progression (up to Approximately 4 Years)

  4. Randomized Phase: Duration of Response (DOR)

    Defined as the time from the first occurrence of a documented confirmed OR to death from any cause or the first occurrence of disease progression as determined by the investigator according to RECIST v1.1, (whichever occurs first)

    Time frame: From Baseline Untill Disease Progression or Death (up to Approximately 4 Years)

  5. Randomized Phase: Percentage of Participants With AEs

    Time frame: From Baseline up to 90 Days After the Final Dose of study treatment or Until Initiation of Another Anti-cancer Therapy (up to Approximately 4 Years)

  6. Percentage of Participants With Symptomatic Treatment Toxicities as Assessed by National Cancer Institute Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE)

    Time frame: Up to Approximately 4 Years

  7. Percentage of Participants Troubled by Treatment Symptoms, as Assessed by Single Item European Organisation for Research and Treatment of Cancer Item Library 46 (EORTC IL46)

    Time frame: Up to Approximately 4 Years

  8. Change From Baseline in Symptomatic Treatment Toxicities as Assessed by PRO-CTCAE

    Time frame: Baseline up to Approximately 4 Years

  9. Change From Baseline in Treatment Side-effect Bother as Assessed by EORTC IL46 item

    Time frame: Baseline up to Approximately 4 Years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Mar 2029, 37 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 7, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Mar 1, 2029
CompletionEst.
Mar 31, 2031
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07323576
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Mar 1, 2029 (estimated)
Completion
Mar 31, 2031 (estimated)
Last update
Feb 9, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inavolisib

Start the discussion